These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34523710)

  • 21.
    Molden E; Jukić MM
    Front Pharmacol; 2021; 12():650750. PubMed ID: 33967790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
    Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
    Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
    Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphic cytochromes P450 and drugs used in psychiatry.
    Coutts RT; Urichuk LJ
    Cell Mol Neurobiol; 1999 Jun; 19(3):325-54. PubMed ID: 10319191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
    de Leon J; Armstrong SC; Cozza KL
    Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.
    Pawlowska M; Bogiel M; Duda J; Sieradzki E
    Eur J Clin Pharmacol; 2015 Jun; 71(6):699-705. PubMed ID: 25953735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genotyping of CYP2D6 and CYP2C19].
    Slanar O; Drazd'áková M; Babiárová K; Pechandová K; Buzková H; Perlík F; Zima T
    Cas Lek Cesk; 2007; 146(9):708-11. PubMed ID: 17966194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.
    Müller DJ; Brandl EJ; Hwang R; Tiwari AK; Sturgess JE; Zai CC; Lieberman JA; Kennedy JL; Richter MA
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):897-903. PubMed ID: 22775532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.
    den Uil MG; Hut HW; Wagelaar KR; Abdullah-Koolmees H; Cahn W; Wilting I; Deneer VHM
    Front Genet; 2023; 14():1249164. PubMed ID: 37693320
    [No Abstract]   [Full Text] [Related]  

  • 37. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
    Ganoci L; Božina T; Mirošević Skvrce N; Lovrić M; Mas P; Božina N
    Drug Metab Pers Ther; 2017 Mar; 32(1):11-21. PubMed ID: 28272018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.